+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
Cipla launches GLYCOHALE respule
19 Mar 2020

Cipla launches GLYCOHALE respule

/
Posted By
/
Comments0
/

Cipla has annouced the introduction of Glycohale Respules. This helps Cipla to strengthen the Respiratory portfolio. Glycopyrrolate inhalation is indicated for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

GLYCOHALE respule is an anticholinergic medicine known as glycopyrrolate.

  • Anticholinergic medicines such as GLYCOHALE respule help the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
  • GLYCOHALE respule is used for maintenance treatment of COPD. COPD is a long-term (chronic) lung disease that includes chronic bronchitis, emphysema, or both.
  • GLYCOHALE respule is for long-term use and should be taken 2 times each day to improve symptoms of COPD for better breathing.
  • GLYCOHALE respule is not used to treat sudden or acute symptoms of COPD. Always have a short-acting beta2-agonist medicine (rescue inhaler) with you to treat sudden symptoms of COPD. If you do not have a rescue inhaler, contact your healthcare provider to have one prescribed for you.

Qualitative and Quantitative Composition

Each 1 ml ampoule contains:

Glycopyrrolate IP……………….…25mcg

Dosage Form(S) and Strength(S)

Glycopyrrolate Inhalation Solution is supplied as a sterile, clear, colorless, aqueous solution for inhalation in a unit-dose single-use LDPE respule. Each 1 mL respule contains 25 mcg of glycopyrrolate.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.